Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

Chromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1, we uncover an oncogenic microRNA gene, MIR21, in a majorit...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yunhua, Xu, Jiangsheng, Choi, Hyun Ho, Han, Cecil, Fang, Yuanzhang, Li, Yujing, Van der Jeught, Kevin, Xu, Hanchen, Zhang, Lu, Frieden, Michael, Wang, Lifei, Eyvani, Haniyeh, Sun, Yifan, Zhao, Gang, Zhang, Yuntian, Liu, Sheng, Wan, Jun, Huang, Cheng, Ji, Guang, Lu, Xiongbin, He, Xiaoming, Zhang, Xinna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226492/
https://www.ncbi.nlm.nih.gov/pubmed/30413718
http://dx.doi.org/10.1038/s41467-018-07264-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226492/
https://www.ncbi.nlm.nih.gov/pubmed/30413718
http://dx.doi.org/10.1038/s41467-018-07264-0

Ejemplares similares